New Agents in the Management of Hyperkalemia

Support for this symposium is provided by an educational grant from ZS Pharma.

Symposium Description and Objectives
Hyperkalemia is a common and vexing problem in CKD and in patients receiving blockers of the renin-angiotensin-aldosterone system. Recently, two new pharmaceutical agents have been developed that offer potential improvements over current approaches to management. This symposium reviews the problem of acute and chronic hyperkalemia, including risks and limitations of current treatment options, and then discusses evidence for safety and efficacy of the new drugs and possible strategies in which they could be deployed.

Upon completion of this symposium, the participant will be able to: 1) describe the prevalence and consequences of hyperkalemia in various patient populations; 2) explain uses and limitations of current therapies for management of hyperkalemia; and 3) discuss new drugs developed for hyperkalemia and how they may offer better options than current approaches.

Symposium Schedule
Friday, November 6, 2015

Introduction
Charles S. Wingo, MD – Moderator
University of Florida

Clinical Hyperkalemia: Consequences and Treatment Strategies
Biff F. Palmer, MD, FASN
University of Texas Southwestern Medical Center

New Agents for Management of Hyperkalemia
Stuart L. Linas, MD, FASN
University of Colorado

Questions and Answers

ASN requires all individuals in a position to control content for Kidney Week 2015 to complete disclosure forms. Responses are listed on the Kidney Week 2015 mobile app, and on the ASN website.